Nicholas Focil Appointed President of hyperCORE International to Drive Global Clinical Research Expansion

hyperCORE International has named Nicholas Focil as its new president, signaling a strategic push to bolster its global clinical research footprint. Focil's nearly two decades of experience in clinical operations and strategic partnerships are anticipated to inject innovative strategies into hyperCORE's operations, especially in tapping into emerging markets and improving trial diversity.

Before joining hyperCORE, Focil founded and led FOMAT Medical Research, a clinical trial organization renowned for its extensive work across more than 70 therapeutic areas in the U.S. and Latin America. His tenure at FOMAT, a charter member of hyperCORE, was marked by a steadfast commitment to ethical, high-quality, and diverse clinical data collection. This background uniquely equips him to steer hyperCORE International toward its next growth phase.

Carlos Orantes, the outgoing president, voiced strong support for Focil's leadership, citing his potential to uphold the network's tradition of excellence and inclusivity. Focil expressed gratitude for Orantes's contributions and the groundwork laid by his predecessors, sharing his eagerness to work with partner sites to expand clinical trial capabilities and accessibility.

With Focil at the helm, hyperCORE International is set to advance its mission of conducting safe, ethical, and timely clinical research. The network's emphasis on efficient patient enrollment and retention, backed by its members' performance and innovation, stands to gain from Focil's forward-thinking leadership and dedication to patient-centric research approaches. For more information on hyperCORE International's initiatives, visit https://www.hypercore.org.